Sionna Therapeutics Inc Dossier - Source-backed chat

Sionna Therapeutics Inc

SIONNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.26

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.10Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $230.3M

Enterprise Value $166.9M

Shares Outstanding 49.9M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Sionna Therapeutics is a clinical-stage biopharmaceutical company targeting the biological root of cystic fibrosis (CF) by stabilizing the first nucleotide-binding domain (NBD1) of the CFTR protein. While the CF market is currently dominated by Vertex Pharmaceuticals, Sionna's first-in-class NBD1 stabilizers (SION-719 and SION-451) offer a mechanism to fully restore CFTR function. Backed by a robust cash runway extending into 2028, the company is approaching critical binary clinical readouts in Summer 2026 that will validate its high-potency pipeline and determine its long-term commercialization path.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$15.17

High · most bullish analyst$63.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0025%

Summer 2026 data readouts reveal safety concerns, such as drug-induced liver injury (elevated LFTs), or fail to meet the minimum efficacy threshold of 8 mmol/L sweat chloride reduction. The clinical viability of the NBD1 stabilizer pipeline is severely compromised, leading to a massive devaluation of the stock, loss of investor confidence, and a halt in future capital funding.

Base CaseCentral scenario

$15.1750%

Matches the consensus mean

Clinical trials show supportive efficacy (sweat chloride reduction of 8-10 mmol/L) and acceptable safety profiles with manageable side effects. Sionna continues to advance its proprietary dual-combination program independently using its existing cash reserves of ~$290M, which fund operations into 2028. The company transitions to Phase 2b trials in late 2026, steadily building value as a credible challenger to Vertex's monopoly.

Bull CaseUpside scenario

$63.0025%

The Summer 2026 clinical readouts for SION-719 and SION-451 demonstrate clean safety profiles with no hepatotoxicity and show a sweat chloride reduction exceeding 10 mmol/L. This validates Sionna's proprietary dual-combination strategy, allowing the company to initiate a Phase 2b dose-ranging study in late 2026. The positive data triggers lucrative strategic partnership discussions with a major pharmaceutical company, significantly de-risking late-stage development and commercialization, and positioning Sionna to capture a substantial share of the multi-billion dollar CF market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class therapeutic approach targeting the NBD1 domain to fully restore CFTR function, addressing the root cause of the F508del mutation.
Strong balance sheet with $289.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing a runway into 2028.
Dual-track clinical strategy (add-on to standard of care and fully proprietary combinations) that diversifies development risk.
Exclusive worldwide license agreement with AbbVie for clinical-stage CF assets, expanding the combination pipeline.

Key Investment Risks

High clinical development risk, as the NBD1 domain is structurally complex and historically difficult to drug successfully.
Entrenched competition from Vertex Pharmaceuticals, which holds a virtual monopoly in the CF space and recently launched its next-generation therapy, Alyftrek.
Safety and toxicity risks, particularly drug-induced liver injury (LFT elevations), which have historically plagued CFTR modulators.
Increasing cash burn rate, with R&D expenses rising to $19.0 million in Q1 2026 as multiple trials run concurrently.

Thesis Invalidation Triggers

Failure of SION-719 to achieve at least an 8 mmol/L reduction in sweat chloride levels during the Phase 2a trial.
Any significant signal of hepatotoxicity or serious adverse events in the Summer 2026 clinical readouts.
Inability to initiate the planned Phase 2b dose-ranging study in the second half of 2026 due to regulatory or clinical delays.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.